EFFECT OF EPLERENONE ON SERUM LEVEL OF SOLUBLE GROWTH-STIMULATING RECEPTOR EXPRESSED BY GENE 2 IN PATIENTS WITH ARTERIAL HYPERTENSION

Authors:

Abstract:

The purpose of the work was to study the dynamics of diastolic function parameters, the content of the soluble growth-stimulating receptor expressed by gene 2 (sST2) and the N-terminal fragment of the brain natriuretic propeptide (NT-proBNP) in the blood of patients with hypertension, when eplerenone is added to antihypertensive therapy. In patients with stage 2 arterial hypertension, addition of eplerenone to antihypertensive therapy contributes to a more pronounced decrease of blood pressure measured by patients during self-monitoring; during daily monitoring compared to antihypertensive therapy. The inclusion of the selective aldosterone mineralocorticoid receptor antagonist eplerenone in the complex therapy of patients with stage 2 arterial hypertension has a pronounced positive effect on the structural and geometric indicators of the myocardium, parameters of the diastolic function of the left ventricle, as well as the content of sST2 and NT-proBNP in the blood serum, along with good tolerability.

Keywords:

hypertension eplerenone diastolic dysfunction echocardiography soluble growth-stimulating receptor expressed by gene 2 N-terminal fragment of brain natriuretic propeptide

References:

1. Agrawal V, Hardas S, Gujar H, Phalgune DS. Correlation of serum ST2 levels with severity of diastolic dysfunction on echocardiography and findings on cardiac MRI in patients with heart failure with preserved ejection fraction. Indian Heart J. 2022;74(3):229-234. Doi: 10.1016/j.ihj.2022.03.001.
2. Aimo A, Gaggin HK, Barison A, Emdin M, Januzzi JL Jr. Imaging, Biomarker, and Clinical Predictors of Cardiac Remodeling in Heart Failure With Reduced Ejection Fraction. JACC Heart Fail. 2019;7(9):782-794. Doi: 10.1016/j.jchf.2019.06.004.
3. Belden Z, Deiuliis JA, Dobre M, Rajagopalan S. The Role of the Mineralocorticoid Receptor in Inflammation: Focus on Kidney and Vasculature. Am J Nephrol. 2017;46(4):298-314. Doi: 10.1159/000480652.
4. Berbenetz NM, Mrkobrada M. Mineralocorticoid receptor antagonists for heart failure: systematic review and meta-analysis. BMC Cardiovasc Disord. 2016;16(1):246. Doi: 10.1186/s12872-016-0425-x.
5. Bozkurt B, Coats AJ, Tsutsui H, Abdelhamid M, Adamopoulos S, Albert N, et al. Universal Definition and Classification of Heart Failure: A Report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure. J Card Fail. 2021 Mar 1:S1071-9164(21)00050-6. Doi: 10.1016/j.cardfail.2021.01.022.
6. Braunwald E. Heart failure. JACC Heart Fail. 2013;1(1):1-20. Doi: 10.1016/j.jchf.2012.10.002.
7. Chou CH, Hung CS, Liao CW, Wei LH, Chen CW, Shun CT, et al; TAIPAI Study Group. IL-6 trans-signalling contributes to aldosterone-induced cardiac fibrosis. Cardiovasc Res. 2018;114(5):690-702. Doi: 10.1093/cvr/cvy013.
8. Dieplinger B, Mueller T. Soluble ST2 in heart failure. Clin Chim Acta. 2015;443:57-70. Doi: 10.1016/j.cca.2014.09.021.
9. Karthigan N, Lockwood S, White A, Yang J, Young MJ. Mineralocorticoid receptor antagonists, heart failure and predictive biomarkers. J Endocrinol. 2022;253(3):R65-R76. Doi: 10.1530/JOE-21-0323.
10. Kubicius A, Bałys M, Ciampi Q, Picano E, Gąsior Z, Haberka M. Diastolic stress echocardiography and biomarkers in patients with preserved left ventricle ejection fraction and heart failure symptoms. Kardiol Pol. 2022 Mar 14. Doi: 10.33963/KP.a2022.0070.
11. Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2015 Jan;28(1):1-39.e14. doi: 10.1016/j.echo.2014.10.003.
12. Nagueh SF, Smiseth OA, Appleton CP, Byrd BF 3rd, Dokainish H, Edvardsen T, et al. Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2016;29(4):277-314. Doi: 10.1016/j.echo.2016.01.011.
13. Najjar E, Faxén UL, Hage C, Donal E, Daubert JC, Linde C, Lund LH. ST2 in heart failure with preserved and reduced ejection fraction. Scand Cardiovasc J. 2019;53(1):21-27. Doi: 10.1080/14017431.2019.1583363.
14. Prior DL, Somaratne JB, Jenkins AJ, Yii M, Newcomb AE, Schalkwijk CG, et al. Calibrated integrated backscatter and myocardial fibrosis in patients undergoing cardiac surgery. Open Heart. 2015;2(1):e000278. Doi: 10.1136/openhrt-2015-000278.

Publication:

«World of Medicine and Biology» Vol. 18 No. 81 (2022) , с. 26-31
УДК 616.12-008.331.1-225.2:616.12-008.1-07

DOI:

https://doi.org/10.26724/2079-8334-2022-3-81-26-31